- Drug Pipelines
- June 2023
- 122 Pages
Global
From €10630EUR$10,995USD£9,130GBP
- Report
- March 2024
- 195 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- January 2024
- 158 Pages
Global
From €3633EUR$3,758USD£3,121GBP
€4036EUR$4,175USD£3,467GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Report
- June 2023
- 57 Pages
Global
From €3862EUR$3,995USD£3,318GBP
- Report
- December 2023
- 111 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- January 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- July 2022
- 100 Pages
Global
From €2659EUR$2,750USD£2,284GBP
- Report
- January 2022
- 200 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,280GBP
- Report
- February 2021
- 36 Pages
Global
€1274EUR$1,318USD£1,094GBP
- Drug Pipelines
- February 2018
- 373 Pages
Global
From €21269EUR$22,000USD£18,269GBP
- Clinical Trials
- February 2020
- 553 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Report
- April 2021
- 48 Pages
Global
€1274EUR$1,318USD£1,094GBP
- Report
- June 2021
- 239 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- June 2021
- 84 Pages
North America
From €1450EUR$1,500USD£1,246GBP
- Report
- June 2021
- 93 Pages
Middle East, Africa
From €1450EUR$1,500USD£1,246GBP
- Report
- June 2021
- 94 Pages
Europe
From €1450EUR$1,500USD£1,246GBP
- Report
- June 2021
- 94 Pages
Asia Pacific
From €1450EUR$1,500USD£1,246GBP
- Drug Pipelines
- September 2020
- 40 Pages
Global
From €1934EUR$2,000USD£1,661GBP
The Thromboembolism Drug market is a subset of the Cardiovascular Drugs market, which focuses on the prevention and treatment of thromboembolic diseases. These drugs are used to reduce the risk of blood clots forming in the arteries and veins, which can lead to serious health complications such as stroke, heart attack, and pulmonary embolism. Thromboembolism drugs are typically anticoagulants, which work by preventing the formation of clots, or thrombolytics, which work by breaking down existing clots.
The Thromboembolism Drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Commonly prescribed drugs include warfarin, heparin, and low molecular weight heparins. Newer drugs such as direct oral anticoagulants (DOACs) are also becoming increasingly popular.
Some of the major companies in the Thromboembolism Drug market include Pfizer, Sanofi, Bayer, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more